Roche closes Igen deal
This article was originally published in The Gray Sheet
Executive Summary
BioVeris stock commences trading on the Nasdaq exchange Feb. 17 under the symbol "BIOV," following completion of Roche Diagnostic's $1.4 bil. acquisition of Igen International (1"The Gray Sheet" July 28, 2003, p. 5). BioVeris, spun-off from Igen, is based in Gaithersburg, Md. and will be led by former Igen management. The firm will assume the ongoing biodefense, lifescience and clinical diagnostic Igen businesses. Former Igen shareholders received $47.25 in cash from Roche and one share of BioVeris for each Igen share held...